Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,totalStockholderEquity,intangibleAssets,capitalSurplus,totalLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,inventory,changeToLiabilities,investments,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,ERYP,25950000.0,26045700,10512000,,-11945000,,-11945000,4173000,1440000,-13245000,-13245000,,-747000,,,,0,1440000,14685000,0,1300000,,-11945000,-11945000,26539000.0,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,en-US,US,EQUITY,True,Nasdaq Real Time Price,6.39,1630509708,0.12999964,6.24,6.43,6.2184,15896,USD,NMS,166432016,-14400000,False,False,REGULAR,2,2.0766714,6.2184 - 6.43,us_market,0,Erytech Pharma S.A.,6.26,6.34,6.39,29,12,finmb_24677080,NasdaqGS,ERYTECH Pharma S.A.,EUR,1089496,122283,2.29,0.5585366,4.1 - 13.0,-6.61,-0.50846153,4.1,13.0,-4.03,-2.8,1.323,5.449167,0.9408331,0.17265633,6.4026375,-0.012637615,-0.0019738139,-2.2821429,4.829932,15,America/New_York,EDT,1.87,,,13.0,4.1,5.45,6.4,1.09M,122.28k,26.05M,,15.85M,0.00%,6.29%,2.46k,0.28,,0.01%,20,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-1,427.93%",,,4.41M,0.22,92.80%,3.72M,-59.11M,-67.66M,-4.03,,44.45M,2.22,27.45M,103.43,,1.32,,,Value,69008,Healthcare,206,"ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.",Lyon,33 4 78 74 44 38,1609372800,France,http://www.erytech.com,86400,60 Avenue Rockefeller,33 4 78 75 56 29,Biotechnology
t-1,ERYP,25950000.0,26045700,14640000,,-19746000,,-19747000,3522000,828000,-17334000,-17334000,,-561000,,,,1000,828000,18162000,0,-2412000,,-19747000,-19747000,26539000.0,589000.0,120705000.0,53863000.0,416000.0,80402000.0,2006000.0,51000.0,-73300000.0,940000.0,-22872000.0,1074000.0,44446000.0,29347000.0,96000.0,-22872000.0,29090000.0,49632000.0,17000.0,8000.0,4334000.0,14379000.0,4706000.0,,0.0,,,,,,,,,,,,,,,,20285000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,6.39,1630509708,0.12999964,6.24,6.43,6.2184,15896,USD,NMS,166432016,-14400000,False,False,REGULAR,2,2.0766714,6.2184 - 6.43,us_market,0,Erytech Pharma S.A.,6.26,6.34,6.39,29,12,finmb_24677080,NasdaqGS,ERYTECH Pharma S.A.,EUR,1089496,122283,2.29,0.5585366,4.1 - 13.0,-6.61,-0.50846153,4.1,13.0,-4.03,-2.8,1.323,5.449167,0.9408331,0.17265633,6.4026375,-0.012637615,-0.0019738139,-2.2821429,4.829932,15,America/New_York,EDT,1.87,,,13.0,4.1,5.45,6.4,1.09M,122.28k,26.05M,,15.85M,0.00%,6.29%,2.46k,0.28,,0.01%,20,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-1,427.93%",,,4.41M,0.22,92.80%,3.72M,-59.11M,-67.66M,-4.03,,44.45M,2.22,27.45M,103.43,,1.32,,,Value,69008,Healthcare,206,"ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.",Lyon,33 4 78 74 44 38,1609372800,France,http://www.erytech.com,86400,60 Avenue Rockefeller,33 4 78 75 56 29,Biotechnology
t-2,ERYP,50432000.0,26045700,14094000,,-18589000,,-18591000,3076000,1041000,-16129000,-16129000,,-2393000,,,,2000,1041000,17170000,0,-2460000,,-18591000,-18591000,51109000.0,,,,,,,,,,,,,,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,,en-US,US,EQUITY,True,Nasdaq Real Time Price,6.39,1630509708,0.12999964,6.24,6.43,6.2184,15896,USD,NMS,166432016,-14400000,False,False,REGULAR,2,2.0766714,6.2184 - 6.43,us_market,0,Erytech Pharma S.A.,6.26,6.34,6.39,29,12,finmb_24677080,NasdaqGS,ERYTECH Pharma S.A.,EUR,1089496,122283,2.29,0.5585366,4.1 - 13.0,-6.61,-0.50846153,4.1,13.0,-4.03,-2.8,1.323,5.449167,0.9408331,0.17265633,6.4026375,-0.012637615,-0.0019738139,-2.2821429,4.829932,15,America/New_York,EDT,1.87,,,13.0,4.1,5.45,6.4,1.09M,122.28k,26.05M,,15.85M,0.00%,6.29%,2.46k,0.28,,0.01%,20,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-1,427.93%",,,4.41M,0.22,92.80%,3.72M,-59.11M,-67.66M,-4.03,,44.45M,2.22,27.45M,103.43,,1.32,,,Value,69008,Healthcare,206,"ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.",Lyon,33 4 78 74 44 38,1609372800,France,http://www.erytech.com,86400,60 Avenue Rockefeller,33 4 78 75 56 29,Biotechnology
t-3,ERYP,84957000.0,26045700,15350000,,-17589000,,-17589000,4488000,747000,-19091000,-19091000,,-121000,,,,0,747000,19838000,0,1820000,,-17589000,-17589000,85560000.0,677000.0,108315000.0,37998000.0,280000.0,89107000.0,1796000.0,,-34962000.0,545000.0,-24040000.0,,45433000.0,22594000.0,,-24040000.0,33302000.0,54012000.0,1116000.0,64000.0,6381000.0,4392000.0,3646000.0,386000.0,1520500.0,-131000.0,-566000.0,1150500.0,1128000.0,11000.0,59000.0,-13870000.0,192500.0,-14624500.0,1254500.0,-14000.0,17500.0,-81500.0,67000.0,-437000.0,31418000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,6.39,1630509708,0.12999964,6.24,6.43,6.2184,15896,USD,NMS,166432016,-14400000,False,False,REGULAR,2,2.0766714,6.2184 - 6.43,us_market,0,Erytech Pharma S.A.,6.26,6.34,6.39,29,12,finmb_24677080,NasdaqGS,ERYTECH Pharma S.A.,EUR,1089496,122283,2.29,0.5585366,4.1 - 13.0,-6.61,-0.50846153,4.1,13.0,-4.03,-2.8,1.323,5.449167,0.9408331,0.17265633,6.4026375,-0.012637615,-0.0019738139,-2.2821429,4.829932,15,America/New_York,EDT,1.87,,,13.0,4.1,5.45,6.4,1.09M,122.28k,26.05M,,15.85M,0.00%,6.29%,2.46k,0.28,,0.01%,20,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-1,427.93%",,,4.41M,0.22,92.80%,3.72M,-59.11M,-67.66M,-4.03,,44.45M,2.22,27.45M,103.43,,1.32,,,Value,69008,Healthcare,206,"ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.",Lyon,33 4 78 74 44 38,1609372800,France,http://www.erytech.com,86400,60 Avenue Rockefeller,33 4 78 75 56 29,Biotechnology
